Titan Pharmaceuticals Stock

TTNP

US8883147055

Market Closed - Nasdaq 04:00:00 29/10/2026 HKT			5-day change	1st Jan Change
0.3360 ^USD	-3.39%		-12.50%	-92.71%

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI

Valuation: Titan Pharmaceuticals

Market Cap	6.13M 5.5M 5.09M 4.61M 8.61M 584M 8.71M 60.82M 24.22M 306M 23.01M 22.53M 970M	P/E 2023	-1.11x	P/E 2024	-0.62x
Enterprise Value	3.3M 2.96M 2.74M 2.48M 4.63M 314M 4.69M 32.74M 13.04M 165M 12.39M 12.13M 522M	EV / Sales 2023	0.11x	EV / Sales 2024	-
Free-Float	-	Yield 2023 *	-	Yield 2024	-

* Estimated data More valuation ratios

Latest news: Titan Pharmaceuticals

04/10/25	Titan Pharmaceuticals announces closing of merger with Black Titan Corporation	RE
02/10/25	Titan Pharmaceuticals, Inc. Appoints Chay Weei Jye as the Sole Director and Acting Secretary, Effective October 1, 2025	CI
01/10/25	Titan Pharmaceuticals, Inc.(NasdaqCM:TTNP) dropped from NASDAQ Composite Index	CI
01/10/25	Ke Sdn. Bhd. completed the acquisition of Titan Pharmaceuticals, Inc. in a reverse merger transaction.	CI
15/08/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
27/06/25	Titan Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
24/06/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Blue Harbour Asset Management L.L.C	CI
15/05/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
12/04/25	Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock	RE
11/04/25	Titan Pharmaceuticals, Inc. announced that it has received $1 million in funding	CI
02/04/25	Titan Pharmaceuticals, Inc. Appoints Gabriel Loh as an Independent Director and Member of the Audit Committee	CI
29/03/25	Titan Pharmaceuticals, Inc. announced that it expects to receive $1 million in funding	CI
21/03/25	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

More news

Analysts' recommendations: Titan Pharmaceuticals

26/05/22	Maxim Downgrades Titan Pharmaceuticals to Hold From Buy	MT
18/02/21	Titan Pharmaceuticals : Maxim Group Upgrades Titan Pharmaceuticals to Buy From Hold, $11 Price Target	MT

More recommendations

Press Releases: Titan Pharmaceuticals

15/08/25	Titan Pharmaceuticals: Q2 Earnings Snapshot	AQ
06/08/25	TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP	BU
28/06/25	Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock	AQ
03/06/25	Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.	AQ
15/05/25	Titan Pharmaceuticals: Q1 Earnings Snapshot	AQ

More press releases

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Employees

Sector

More about the company

Quotes

Date	Price	Change
28/10/26	US$0.3360	-3.39%
27/10/26	US$0.3478	-4.45%
26/10/26	US$0.3640	-0.68%
23/10/26	US$0.3665	+1.98%
22/10/26	US$0.3594	-6.41%

Delayed Quote Nasdaq

More quotes

3 years	0		14.8
5 years	0		35.6
10 years	0		17,280.02

	2023	2024
Net sales	184K 165K 153K 138K 258K 17.52M 261K 1.82M 727K 9.17M 690K 676K 29.11M	-
Net income	-5.57M -5M -4.62M -4.18M -7.82M -530M -7.91M -55.23M -22M -278M -20.9M -20.46M -881M	-4.71M -4.22M -3.9M -3.54M -6.61M -448M -6.68M -46.67M -18.59M -235M -17.66M -17.29M -745M
Net Debt	-6.2M -5.56M -5.14M -4.65M -8.69M -590M -8.8M -61.44M -24.47M -309M -23.25M -22.76M -980M	-2.83M -2.54M -2.35M -2.13M -3.97M -270M -4.02M -28.08M -11.18M -141M -10.62M -10.4M -448M

Titan Pharmaceuticals Stock

Stocks

TTNP

US8883147055

Valuation: Titan Pharmaceuticals

Chart: Titan Pharmaceuticals

Latest news: Titan Pharmaceuticals

Analysts' recommendations: Titan Pharmaceuticals

Press Releases: Titan Pharmaceuticals

Quotes and Performance

Price Extremes

Financials

Company Profile

Quotes

1 day	-3.39%
Current month	-92.71%
Current year	-92.71%